Insider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases $134,261.64 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 14,562 shares of the stock in a transaction dated Monday, February 3rd. The stock was purchased at an average price of $9.22 per share, with a total value of $134,261.64. Following the acquisition, the insider now owns 5,012,796 shares of the company’s stock, valued at $46,217,979.12. The trade was a 0.29 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, January 30th, Venrock Healthcare Capital Par acquired 43,707 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average cost of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Stock Performance

KALV stock opened at $9.90 on Thursday. The stock has a fifty day moving average of $8.80 and a 200-day moving average of $10.77. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $16.88. The company has a market capitalization of $489.26 million, a price-to-earnings ratio of -2.72 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. Equities analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its position in shares of KalVista Pharmaceuticals by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after acquiring an additional 3,314 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $153,000. China Universal Asset Management Co. Ltd. lifted its holdings in KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 3,328 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its stake in KalVista Pharmaceuticals by 23.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after purchasing an additional 121,615 shares during the period. Finally, Emerald Advisers LLC grew its holdings in KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after buying an additional 192,091 shares in the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on KALV shares. Bank of America initiated coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. TD Cowen began coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).